8d09f2ad054126fa…

{
  "id": "NCT00082602",
  "type": "Study",
  "data": {
    "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.",
    "completionDate": "2005-04",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 83,
    "enrollmentType": "ACTUAL",
    "nctId": "NCT00082602",
    "phase": "PHASE3",
    "sponsorId": "johnson-johnson-pharmaceutical-research-development-l-l-c",
    "startDate": "2004-05",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00082602"
  }
}